Chronic weight management in adults with obesity or overweight
Amount
5-120 mg (titrated)
Frequency
Once daily
Duration
36 weeks (Phase 2b trial)
Route
OralTiming
Start at 5 mg daily with 4-week titration to maintenance doses of 45, 90, or 120 mg once daily. No injection required.
Duration
Ongoing (long-term use expected)
Repeatable
Yes
CMP (Comprehensive Metabolic Panel)
When: Baseline
Why: Baseline liver and kidney function
Lipid panel
When: Baseline
Why: Baseline cardiovascular risk assessment
HbA1c
When: Baseline
Why: Baseline glycemic status
CMP
When: 12 weeks
Why: Monitor liver and kidney function during treatment
Get free access to all content plus biweekly research updates.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Aleniglipron (GPCR0803) is an investigational oral small molecule GLP-1 receptor agonist developed by Structure Therapeutics. It represents a new generation of GLP-1 therapies that move beyond injectable peptides to offer patients an oral pill option with competitive weight loss efficacy.
Unlike peptide-based GLP-1 agonists such as semaglutide and tirzepatide, aleniglipron is a non-peptide small molecule. This means it does not require injection and avoids the manufacturing complexity of peptide synthesis. It is taken as a once-daily oral tablet with a standard titration schedule.
Structure Therapeutics announced positive Phase 2b results from the ACCESS clinical program in December 2025. The data support advancement to Phase 3, planned for mid-2026.
Aleniglipron activates the GLP-1 receptor through a small molecule binding mechanism distinct from the orthosteric peptide binding site used by native GLP-1 and peptide analogs.
The Phase 2b ACCESS program demonstrated competitive weight loss with once-daily oral dosing. The 120 mg dose achieved 11.3% placebo-adjusted weight loss at 36 weeks, while the exploratory 240 mg dose showed up to 15.3%. The tolerability profile was consistent with the GLP-1 agonist class, with an overall discontinuation rate of approximately 10% across active arms.
Phase 2b ACCESS Study of Aleniglipron in Adults with Obesity or Overweight, published in Press release (Structure Therapeutics) (Structure Therapeutics investigators, 2025):
ACCESS II Exploratory Study of Higher-Dose Aleniglipron, published in Press release (Structure Therapeutics) (Structure Therapeutics investigators, 2025):
We summarize new studies, safety updates, and dosing insights โ delivered biweekly.
See real-world usage patterns alongside the clinical evidence above. Community-sourced, not clinically verified.
0View community protocolsSemaglutide: FDA-approved GLP-1 agonist for weight loss and diabetes. Covers STEP/SUSTAIN trials, Ozempic vs Wegovy dosing, and cardiovascular benefits.
Tirzepatide: FDA-approved dual GIP/GLP-1 agonist with up to 22.5% weight loss. Covers SURPASS/SURMOUNT trials, dosing, and semaglutide comparison.
Orforglipron (LY3502970): oral non-peptide GLP-1 agonist by Eli Lilly. ATTAIN Phase 3 showed 11.2% weight loss at 72 weeks. Mechanism, dosing, and status.
Survodutide: Glucagon/GLP-1 dual agonist for obesity and MASH. Covers Phase 3 trials, liver fat reduction, weight loss data, dosing, and side effects.
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.
Every GLP-1 and incretin drug ranked by clinical weight loss data as of 2026, from retatrutide at 28.7% to oral orforglipron at 11.2%, with comparison tables and trial details.
A comprehensive guide to every oral GLP-1 obesity drug in development, from approved oral semaglutide to pipeline agents orforglipron, aleniglipron, VK2735, ribupatide, and amycretin.
A head-to-head comparison of oral and injectable GLP-1 drugs for obesity, including oral semaglutide, orforglipron, aleniglipron, and VK2735 versus their injectable counterparts.
Related content you may find interesting